VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, aiming to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., announced on October 7, 2026, that it is implementing New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays and computational modeling.
The strategy supports the development of the company’s BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for the treatment of cancer. According to the announcement, new three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates.
Why this matters: The adoption of NAMs aligns with FDA guidance and could improve the translational relevance of preclinical findings, potentially accelerating the development of effective cancer therapies while addressing ethical concerns about animal testing. For investors, this strategic shift may enhance the company’s pipeline value and operational efficiency.
In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity.
For more details on VERAXA Biotech’s initiatives, visit their client partner page or read the full announcement here. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
The announcement was distributed through MissionIR, a specialized communications platform. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For more information, visit MissionIR.
